These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30013414)

  • 1. Combination of Empagliflozin and Metformin Therapy: A Consideration of its Place in Type 2 Diabetes Therapy.
    Goldman JD
    Clin Med Insights Endocrinol Diabetes; 2018; 11():1179551418786258. PubMed ID: 30013414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of empagliflozin plus metformin for the treatment of type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Saf; 2018 Aug; 17(8):837-848. PubMed ID: 30068236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
    Jain RK
    Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes.
    Hu J; Zou P; Zhang S; Zhou M; Tan X
    Expert Opin Pharmacother; 2016 Dec; 17(18):2471-2477. PubMed ID: 27819159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin added to metformin and sulfonylurea therapy in patients with sub-optimally controlled type 2 diabetes mellitus.
    Lewin AJ; Frías JP
    Expert Opin Pharmacother; 2015 Apr; 16(5):781-4. PubMed ID: 25644093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin for the treatment of type 2 diabetes.
    Jahagirdar V; Barnett AH
    Expert Opin Pharmacother; 2014 Nov; 15(16):2429-41. PubMed ID: 25301180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Options for empagliflozin in combination therapy in type 2 diabetes mellitus.
    Hershon KS
    Int J Gen Med; 2016; 9():155-72. PubMed ID: 27307761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
    Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus.
    Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P
    Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms linking empagliflozin to cardiovascular and renal protection.
    Perrone-Filardi P; Avogaro A; Bonora E; Colivicchi F; Fioretto P; Maggioni AP; Sesti G; Ferrannini E
    Int J Cardiol; 2017 Aug; 241():450-456. PubMed ID: 28395981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.
    Anderson JE; Wright EE; Shaefer CF
    Diabetes Ther; 2017 Feb; 8(1):33-53. PubMed ID: 27837465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin: A Review in Type 2 Diabetes.
    Frampton JE
    Drugs; 2018 Jul; 78(10):1037-1048. PubMed ID: 29946963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin.
    Blevins T
    Expert Opin Drug Saf; 2015 May; 14(5):789-93. PubMed ID: 25789798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
    Dailey GE
    Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R
    Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin.
    Ahmann A
    Drugs Context; 2015; 4():212288. PubMed ID: 26633984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.